21
total announcements
539997.BO · 15 min delayed
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced the regularization of Mr. Swanith Kapoor as Non-Executive Independent Director and reappointment of Mr. Aditya Arora as Whole Time Director, both for a term of 5 years.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced the Scrutinizer Report of AGM E-Voting, which reveals that all resolutions at the 43rd AGM were passed with requisite majority. The report includes voting results for six resolutions, with the highest number of votes in favor of the first resolution to adopt the Audited Standalone Financial Statements for FY 2025-26.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd held its 43rd Annual General Meeting on August 31, 2026, through video conferencing. The meeting was attended by 34 members, and resolutions related to audited financial statements, director appointments, and cost auditor remuneration were passed.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has published unaudited financial results for the quarter ended June 30, 2026, as per the requirement of Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has published a notice of its 43rd Annual General Meeting in the Financial Express and Punjabi Jagran newspapers on August 10, 2026, to be held on August 31, 2026.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd held an Investors/Analysts Meeting on August 10, 2026, where the management discussed the company's business operations, performance, and outlook, without sharing any unpublished price sensitive information.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced its Q1 FY27 earnings conference call transcript, with management discussing revenue growth, EBITDA margins, and new product registrations. The company expects INR700 crores in sales revenue for FY27 and EBITDA margins between 26% to 27%. Management also discussed the delay in oncology registrations and the progress of clinical trials for Erythropoietin.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has five operational units, including biologicals, general facility, oncology, cephalosporin, and beta-lactam, with a sixth unit to be commenced by November 2026. The company expects a total sales revenue of INR700 crores in FY27 with EBITDA margins between 26% to 27%. The management is registering new molecules every quarter-on-quarter, showing growth in revenue.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has raised its FY27 guidance for revenue and profitability, citing strong execution and clear visibility. The company has also highlighted its expertise in complex formulation, research, and manufacturing, with a broad and diverse product offering across 25+ therapeutic areas. The announcement includes forward-looking statements and cautions against relying on them for future performance.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd reported a strong Q1FY27 with 46% YoY revenue growth, 13% YoY EBITDA growth, and 119% YoY PAT growth. The company raised FY27 guidance across all key metrics.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd reported a strong start to FY27 with 46% YoY revenue growth, 13% YoY EBITDA growth, and 119% YoY PAT growth. The company has raised FY27 guidance across all key metrics.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced its 43rd AGM, to be held on August 31, 2026, through video conferencing. The company has achieved its target of doubling its revenue by FY26, with consolidated revenue from operations of ₹503 crore. Profit After Tax rose 69% year-on-year, and EBITDA margins expanded by 200 basis points.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced its Annual Report for FY 2025-26, with revenue from operations reaching ₹503 crore, a 36% increase from ₹370 crore in FY25. Profit After Tax rose 69% year-on-year to ₹67.3 crore, with PAT margins expanding to 13.4% and EBITDA margins increasing by 200 basis points to 24%. The company has also tightened inventory management and payables, improving its cash conversion cycle from 208 days to 170 days.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced the closure of its register of members and share transfer books from August 25 to August 31, 2026, for the purpose of its 43rd Annual General Meeting.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has informed the BSE about the intimation of its 43rd Annual General Meeting (AGM) to be held on August 31, 2026, through video conference.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced the outcome of its Board Meeting, including the re-appointment of Mr. Aditya Arora as Whole Time Director for a further period of five years, the regularization of Mr. Swanith Kapoor as an Independent Director, and the appointment of M/s Verma Khushwinder & Co. as Cost Auditors for the financial year 2026-27.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced an earnings conference call for Q1 FY 2026-27, scheduled to be held on August 10, 2026. The call will be hosted by Go India Advisors and will feature company participants Ramesh Kumar and Aditya Arora.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced an earnings conference call for Q1 FY 2026-27, scheduled to be held on August 10, 2026, at 4:00 P.M. IST. The call will be hosted by Go India Advisors and will feature company participants Ramesh Kumar, Managing Director, and Aditya Arora, Director & CFO.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has announced an earnings conference call for Q1 FY 2026-27, scheduled on August 10, 2026, at 4:00 P.M. IST. The call will be hosted by Go India Advisors and will feature company participants Ramesh Kumar, Managing Director, and Aditya Arora, Director & CFO.
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd has scheduled a board meeting on August 10, 2026, to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.